Hubei Jumpcan Pharmaceutical Co Ltd (600566) — Capital Reinvestment Ratio
Hubei Jumpcan Pharmaceutical Co Ltd (600566) has a Capital Reinvestment Ratio of 0.09x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥178.57 Million) in capital expenditures (CN¥15.27 Million). Check how tangible is Hubei Jumpcan Pharmaceutical Co Ltd's equity to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Hubei Jumpcan Pharmaceutical Co Ltd Capital Reinvestment Ratio (2000–2025)
This chart tracks Hubei Jumpcan Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 25 annual periods. For the full cash flow conversion analysis, see 600566 cash flow metrics.
Annual Capital Reinvestment Ratio for Hubei Jumpcan Pharmaceutical Co Ltd (2000–2025)
Year-by-year Capital Reinvestment Ratio for Hubei Jumpcan Pharmaceutical Co Ltd from 2000 to 2025. See cash generation quality of Hubei Jumpcan Pharmaceutical Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.08x | CN¥1.20 Billion | CN¥95.86 Million | ▼ -0.1% |
| 2024 | 0.08x | CN¥2.18 Billion | CN¥174.34 Million | ▼ -8.0% |
| 2023 | 0.09x | CN¥3.46 Billion | CN¥301.64 Million | ▼ -6.3% |
| 2022 | 0.09x | CN¥2.62 Billion | CN¥243.66 Million | ▼ -29.1% |
| 2021 | 0.13x | CN¥1.89 Billion | CN¥248.32 Million | ▼ -45.6% |
| 2020 | 0.24x | CN¥1.78 Billion | CN¥429.63 Million | ▼ -5.2% |
| 2019 | 0.25x | CN¥2.15 Billion | CN¥546.44 Million | ▼ -34.9% |
| 2018 | 0.39x | CN¥1.71 Billion | CN¥668.06 Million | ▼ -37.7% |
| 2017 | 0.63x | CN¥1.19 Billion | CN¥746.25 Million | ▲ +77.2% |
| 2016 | 0.35x | CN¥913.10 Million | CN¥323.49 Million | ▼ -42.2% |
| 2015 | 0.61x | CN¥645.48 Million | CN¥395.98 Million | ▲ +25.4% |
| 2014 | 0.49x | CN¥616.11 Million | CN¥301.51 Million | ▼ -48.0% |
| 2013 | 0.94x | CN¥287.16 Million | CN¥270.10 Million | ▼ -43.1% |
| 2012 | 1.65x | CN¥27.01 Million | CN¥44.67 Million | ▼ -98.9% |
| 2011 | 147.69x | CN¥411.24K | CN¥60.74 Million | ▲ +9770.9% |
| 2010 | 1.50x | CN¥51.13 Million | CN¥76.50 Million | ▲ +2.4% |
| 2009 | 1.46x | CN¥4.92 Million | CN¥7.19 Million | ▲ +304.4% |
| 2008 | 0.36x | CN¥23.05 Million | CN¥8.33 Million | ▲ +69.4% |
| 2007 | 0.21x | CN¥36.72 Million | CN¥7.83 Million | ▼ -98.3% |
| 2006 | 12.22x | CN¥4.24 Million | CN¥51.83 Million | ▲ +1194.8% |
| 2005 | 0.94x | CN¥63.38 Million | CN¥59.80 Million | ▼ -94.7% |
| 2003 | 17.83x | CN¥2.24 Million | CN¥39.99 Million | ▲ +235.0% |
| 2002 | 5.32x | CN¥22.00 Million | CN¥117.09 Million | ▼ -55.1% |
| 2001 | 11.86x | CN¥7.43 Million | CN¥88.07 Million | ▲ +1349.6% |
| 2000 | 0.82x | CN¥23.73 Million | CN¥19.41 Million | — |